RU2286797C2 - Применение cd25-связывающих молекул для лечения воспалительных заболеваний желудочно-кишечного тракта - Google Patents

Применение cd25-связывающих молекул для лечения воспалительных заболеваний желудочно-кишечного тракта Download PDF

Info

Publication number
RU2286797C2
RU2286797C2 RU2002127800/15A RU2002127800A RU2286797C2 RU 2286797 C2 RU2286797 C2 RU 2286797C2 RU 2002127800/15 A RU2002127800/15 A RU 2002127800/15A RU 2002127800 A RU2002127800 A RU 2002127800A RU 2286797 C2 RU2286797 C2 RU 2286797C2
Authority
RU
Russia
Prior art keywords
gastrointestinal tract
disease
inflammatory diseases
basiliximab
treatment
Prior art date
Application number
RU2002127800/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2002127800A (ru
Inventor
Хансйёрг АДАМ (DE)
Хансйёрг АДАМ
Лотар ФЭРБЕР (DE)
Лотар ФЭРБЕР
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2002127800A publication Critical patent/RU2002127800A/ru
Application granted granted Critical
Publication of RU2286797C2 publication Critical patent/RU2286797C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2002127800/15A 2000-03-30 2001-03-28 Применение cd25-связывающих молекул для лечения воспалительных заболеваний желудочно-кишечного тракта RU2286797C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0007911.1 2000-03-30
GBGB0007911.1A GB0007911D0 (en) 2000-03-30 2000-03-30 Organic compounds

Publications (2)

Publication Number Publication Date
RU2002127800A RU2002127800A (ru) 2004-03-27
RU2286797C2 true RU2286797C2 (ru) 2006-11-10

Family

ID=9888901

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002127800/15A RU2286797C2 (ru) 2000-03-30 2001-03-28 Применение cd25-связывающих молекул для лечения воспалительных заболеваний желудочно-кишечного тракта

Country Status (18)

Country Link
US (2) US20050226872A1 (cg-RX-API-DMAC7.html)
EP (1) EP1268553A1 (cg-RX-API-DMAC7.html)
JP (1) JP2003528890A (cg-RX-API-DMAC7.html)
KR (2) KR20020084107A (cg-RX-API-DMAC7.html)
CN (1) CN1416432A (cg-RX-API-DMAC7.html)
AU (2) AU2001246516B2 (cg-RX-API-DMAC7.html)
BR (1) BR0109549A (cg-RX-API-DMAC7.html)
CA (1) CA2401249A1 (cg-RX-API-DMAC7.html)
GB (1) GB0007911D0 (cg-RX-API-DMAC7.html)
HU (1) HUP0301846A3 (cg-RX-API-DMAC7.html)
IL (1) IL151089A0 (cg-RX-API-DMAC7.html)
NO (1) NO20024579L (cg-RX-API-DMAC7.html)
NZ (1) NZ520547A (cg-RX-API-DMAC7.html)
PL (1) PL357014A1 (cg-RX-API-DMAC7.html)
RU (1) RU2286797C2 (cg-RX-API-DMAC7.html)
SK (1) SK13892002A3 (cg-RX-API-DMAC7.html)
WO (1) WO2001072845A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200207736B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2500427C2 (ru) * 2010-07-15 2013-12-10 Олег Ильич Эпштейн Лекарственное средство для лечения функциональных нарушений желудочно-кишечного тракта и способ лечения функциональных нарушений желудочно-кишечного тракта

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081508A2 (en) * 2001-04-06 2002-10-17 University Of Bristol Use of cd25 binding molecules in steroid-resistant patients
WO2009086197A1 (en) * 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
EP2438442B1 (en) 2008-12-01 2017-08-09 Laboratory Corporation of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
US20100233732A1 (en) * 2009-01-15 2010-09-16 Laboratory Corporation Of America Holdings Methods of Determining Patient Response By Measurement of HER-2 Expression
BRPI1007321A2 (en) 2009-01-15 2018-07-10 Laboratory Corporation Of America Holdings methods for measuring and / or quantifying the presence and / or amount of her-3 or her-3 in a complex in a patient sample, and to determine if an individual with cancer is likely to respond to treatment with a targeted therapy. and antibody.
UY34054A (es) * 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
CA3045944A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
DE69937057T2 (de) * 1998-07-27 2008-05-29 Novartis Ag Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2500427C2 (ru) * 2010-07-15 2013-12-10 Олег Ильич Эпштейн Лекарственное средство для лечения функциональных нарушений желудочно-кишечного тракта и способ лечения функциональных нарушений желудочно-кишечного тракта

Also Published As

Publication number Publication date
NO20024579D0 (no) 2002-09-24
IL151089A0 (en) 2003-04-10
PL357014A1 (en) 2004-07-12
AU2001246516B2 (en) 2005-06-30
CA2401249A1 (en) 2001-10-04
NZ520547A (en) 2005-04-29
RU2002127800A (ru) 2004-03-27
WO2001072845A1 (en) 2001-10-04
US20050226872A1 (en) 2005-10-13
SK13892002A3 (sk) 2003-05-02
HUP0301846A3 (en) 2010-07-28
CN1416432A (zh) 2003-05-07
KR20080079702A (ko) 2008-09-01
ZA200207736B (en) 2003-05-08
EP1268553A1 (en) 2003-01-02
KR20020084107A (ko) 2002-11-04
GB0007911D0 (en) 2000-05-17
JP2003528890A (ja) 2003-09-30
NO20024579L (no) 2002-11-11
US20090041775A1 (en) 2009-02-12
HUP0301846A2 (hu) 2003-09-29
BR0109549A (pt) 2003-06-10
AU4651601A (en) 2001-10-08

Similar Documents

Publication Publication Date Title
US20090041775A1 (en) Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract
JP2002502824A (ja) 同種移植における補刺激遮断および混合キメラ現象
JP2022105160A (ja) 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ－ｃｓｆ
RU2723047C2 (ru) Средство для лечения множественной миеломы (ММ)
TW201902514A (zh) Ｐｄ－１抗體與ｖｅｇｆ配體或ｖｅｇｆ受體抑制劑聯合在製備治療腫瘤的藥物中的用途
EA006314B1 (ru) Способ ингибирования прогрессивного развития или стабилизации волчаночного нефрита
AU748533B2 (en) Composition and method to prevent graft rejection and other counter-adaptive T lymphocyte mediated immune responses
AU2003247813C1 (en) Method for the treatment of multiple sclerosis
US20130078238A1 (en) Methods and Compositions for Treating Hepatitis with Anti-CD3 Immune Molecule Therapy
KR20190090894A (ko) 관절염 치료
AU2001246516A1 (en) Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract
JP2003528890A5 (cg-RX-API-DMAC7.html)
ES2348984T3 (es) Procedimientos de tratamiento de la aterosclerosis.
CA2759231A1 (en) Methods for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients
JP3973360B2 (ja) 関節リウマチまたは皮膚疾患の処置に使用するためのｃｄ２５結合分子
CZ20032672A3 (cs) CD25 vazebná molekula pro použití při prevenci nebo léčení některých nemocí u pacientů rezistentních na léčbu steroidy
JPH07500330A (ja) 関節のＴ細胞介在炎症の治療のためのＣＤｗ５２特異抗体
RU2025103940A (ru) Антитела к tl1a для лечения язвенного колита и болезни крона
RU2822135C2 (ru) Способы лечения хронического резервуарного илеита
EP4334351A1 (en) Treatment for systemic lupus erythematosus using anti-baffr antibodies
Fabre Monoclonal anti lymphocyte antibodies as immunosuppressive reagents for clinical practice
Albenberg et al. Biologics for the treatment of moderate-to-severe ulcerative colitis in pediatric patients